Modality
ADC
MOA
TROP-2 ADC
Target
FGFR
Pathway
Notch
PsACKD
Development Pipeline
Preclinical
Sep 2025
→ Feb 2025
PreclinicalCurrent
NCT04739502
516 pts·CKD
2025-09→2025-02·Terminated
516 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-171.1y agoInterim· CKD
Trial Timeline
Q2Q3
Preclinical
Termina…
Catalysts
Interim
2025-02-17 · 1.1y ago
CKD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04739502 | Preclinical | CKD | Terminated | 516 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Surarasimod | Xenon Pharma | Phase 2 | SHP2 | |
| Tixatapinarof | Recursion | Approved | FGFR |